QED Clinical Services, a global niche CRO operating in more than 40 countries, has announced that it will address the increasing demand of biotech and pharma companies to develop drugs in rare disease areas.
The company’s CEO, Thomas Ogorka summarised QED’s strategy moving forward: “We can clearly see a strong industry trend for orphan drug development activities. Any company developing drugs for orphan indications needs a service provider who can not only offer tailor-made solutions in a very effective and attentive way, but also has to have access to these rare patient populations no matter where in the world. QED’s new “OrphanReach” division offers our Sponsors exactly that: a lean management structure with excellent client attention and at the same time the global reach element which one would have thought only the largest CROs can provide. QED is a good example that a combination of an innovative operational model can work perfectly well within “niche” areas like the development of orphan & rare disease drugs.”